ivWatch, a leading IV safety company, has announced strategic ivWatch distribution partnerships with Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman. These exclusive agreements will help promote, sell, and support ivWatch’s continuous monitoring products in these markets, expanding the availability of continuous IV monitoring solutions globally. The partnerships align with ivWatch’s mission to advance patient safety by detecting IV infiltrations and extravasations at their earliest stages, enabling clinicians to improve their decision-making with real-time data. The company’s innovative technology, which uses visible and near-infrared light to measure changes near an IV insertion site, has received FDA clearance and holds over 60 patents worldwide.
Introduction
From ivWatch
Company Strengthens International Expansion
Newport News, VA, August 10, 2022
ivWatch, LLC, an innovative IV safety company working to eliminate the harm caused by infiltration and extravasation events, announced three new strategic distribution partnerships internationally. Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman have each signed exclusive agreements to promote, sell, and support ivWatch’s continuous monitoring products in their markets. ivWatch’s novel technologies will complement and bolster their existing portfolios of intravenous products provided to hospitals and other health care facilities.
Expanding Availability of Continuous IV Monitoring Solutions
ivWatch solutions continue to be available in more countries throughout the globe and with the addition of Austria, Kuwait, and Oman, clinicians will now be able to improve their bedside decision-making with real-time IV infiltration data. Continuous IV site monitoring provides accurate and precise insights to detect infiltrations and extravasations at their earliest stages. ivWatch’s proprietary algorithm detects infiltrations promptly and notifies clinicians of adverse IV therapy events often hours before they are detectable by visual or tactile examination.1
Partnerships and Mission
“At ivWatch, we are on a steadfast mission to improve IV safety globally and we are extremely passionate about partnering with like-minded innovators who share that same relentless pursuit to advance patient safety,” said Chuck Egress, Vice President of Business Development and Emerging Markets at ivWatch. “IV infiltrations and extravasations are a major global patient safety concern, and these new partnerships provide increased access to advanced safety solutions to help end complications and improve patient outcomes in IV therapy.”
Technological Advancements
ivWatch has over 60 patents worldwide and received its first FDA clearance in 2015 for its IV site monitoring system that consists of an ivWatch Patient Monitor and a reusable optical biosensor that uses visible and near-infrared light to continuously measure changes in the optical properties of the tissue near an IV insertion site. In 2020, the company expanded its portfolio of sensor solutions and received FDA clearance for a single-use, miniaturized biosensor that is cleared for all patient age groups, sizes, and skin tones. Both sensors work seamlessly with the intuitive user interface on the Patient Monitor, which issues audible and visual “Check IV” alerts for the clinician to assess the IV site. ivWatch technology performs with high accuracy, intelligence, and low false alarm rates, which is critical to improving patient outcomes.
About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. Using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV site monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.
Media Contact
MEDIA CONTACT: Erin Wendell erin.wendell@ivwatch.com Mobile (757) 633-4688
Question & Answer
What partnerships has ivWatch recently announced?
ivWatch has recently announced strategic distribution partnerships with Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman.
What is the goal of these distribution partnerships?
These exclusive agreements aim to promote, sell, and support ivWatch’s continuous monitoring products in these markets, expanding the availability of continuous IV monitoring solutions globally.
How does ivWatch’s technology work?
ivWatch’s technology uses visible and near-infrared light to measure changes near an IV insertion site, enabling clinicians to detect IV infiltrations and extravasations at their earliest stages.
What is ivWatch’s mission?
ivWatch’s mission is to advance patient safety by improving IV safety globally and partnering with innovators who share the same goal of enhancing patient outcomes in IV therapy.
